Limits...
CSF isoprostane levels are a biomarker of oxidative stress in multiple sclerosis.

Mir F, Lee D, Ray H, Sadiq SA - Neurol Neuroimmunol Neuroinflamm (2014)

Bottom Line: We found increased CSF levels of 8-iso-PGF2α in patients with MS compared to controls, with the most striking values in a subgroup of patients with SPMS.Furthermore, the increase in 8-iso-PGF2α correlated with other parameters of lipid peroxidation as well as with a decrease in the total antioxidant status in the MS CSF samples.Further investigation will help establish the pathologic and clinical significance of our preliminary findings.

View Article: PubMed Central - PubMed

Affiliation: Tisch MS Research Center of New York, New York, NY.

ABSTRACT

Objective: To investigate the potential of 8-iso-prostaglandin F2α (8-iso-PGF2α) as a biomarker for disease activity and oxidative stress in the CSF of patients with multiple sclerosis (MS).

Methods: The isoprostane 8-iso-PGF2α is an established biomarker for in vivo oxidative stress and lipid peroxidation. We measured CSF 8-isoPGF2α levels in 231 patients with MS (74 with relapsing-remitting MS, 67 with primary progressive MS, and 90 with secondary progressive MS [SPMS]) and 40 controls using a competition ELISA.

Results: We found increased CSF levels of 8-iso-PGF2α in patients with MS compared to controls, with the most striking values in a subgroup of patients with SPMS. Furthermore, the increase in 8-iso-PGF2α correlated with other parameters of lipid peroxidation as well as with a decrease in the total antioxidant status in the MS CSF samples.

Conclusions: Our study demonstrates that CSF levels of 8-iso-PGF2α may serve as a biomarker of oxidative stress in MS. Further investigation will help establish the pathologic and clinical significance of our preliminary findings.

No MeSH data available.


Related in: MedlinePlus

Total antioxidant status (TAS) (nonenzymatic)TAS of CSF samples was determined in controls and patients with MS. Groups were statistically compared using GraphPad Prism 5.0. * indicates statistical significance with a p value of <0.05. PPMS = primary progressive multiple sclerosis; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary progressive MS.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4202929&req=5

Figure 3: Total antioxidant status (TAS) (nonenzymatic)TAS of CSF samples was determined in controls and patients with MS. Groups were statistically compared using GraphPad Prism 5.0. * indicates statistical significance with a p value of <0.05. PPMS = primary progressive multiple sclerosis; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary progressive MS.

Mentions: The antioxidant status of patients with MS was also investigated. TAS as determined by the overall nonenzymatic antioxidant capacity samples showed a decrease (p < 0.0001) in the CSF of patients with MS (n = 231; mean ± SD = 121.8 ± 45.3 mMol) compared to the control CSF samples (n = 40; 258.3 ± 113.3 mMol), as shown in figure 3. The TAS was most uniformly reduced in progressive forms of MS, with the most pronounced decrease observed in the SPMS group.


CSF isoprostane levels are a biomarker of oxidative stress in multiple sclerosis.

Mir F, Lee D, Ray H, Sadiq SA - Neurol Neuroimmunol Neuroinflamm (2014)

Total antioxidant status (TAS) (nonenzymatic)TAS of CSF samples was determined in controls and patients with MS. Groups were statistically compared using GraphPad Prism 5.0. * indicates statistical significance with a p value of <0.05. PPMS = primary progressive multiple sclerosis; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary progressive MS.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4202929&req=5

Figure 3: Total antioxidant status (TAS) (nonenzymatic)TAS of CSF samples was determined in controls and patients with MS. Groups were statistically compared using GraphPad Prism 5.0. * indicates statistical significance with a p value of <0.05. PPMS = primary progressive multiple sclerosis; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary progressive MS.
Mentions: The antioxidant status of patients with MS was also investigated. TAS as determined by the overall nonenzymatic antioxidant capacity samples showed a decrease (p < 0.0001) in the CSF of patients with MS (n = 231; mean ± SD = 121.8 ± 45.3 mMol) compared to the control CSF samples (n = 40; 258.3 ± 113.3 mMol), as shown in figure 3. The TAS was most uniformly reduced in progressive forms of MS, with the most pronounced decrease observed in the SPMS group.

Bottom Line: We found increased CSF levels of 8-iso-PGF2α in patients with MS compared to controls, with the most striking values in a subgroup of patients with SPMS.Furthermore, the increase in 8-iso-PGF2α correlated with other parameters of lipid peroxidation as well as with a decrease in the total antioxidant status in the MS CSF samples.Further investigation will help establish the pathologic and clinical significance of our preliminary findings.

View Article: PubMed Central - PubMed

Affiliation: Tisch MS Research Center of New York, New York, NY.

ABSTRACT

Objective: To investigate the potential of 8-iso-prostaglandin F2α (8-iso-PGF2α) as a biomarker for disease activity and oxidative stress in the CSF of patients with multiple sclerosis (MS).

Methods: The isoprostane 8-iso-PGF2α is an established biomarker for in vivo oxidative stress and lipid peroxidation. We measured CSF 8-isoPGF2α levels in 231 patients with MS (74 with relapsing-remitting MS, 67 with primary progressive MS, and 90 with secondary progressive MS [SPMS]) and 40 controls using a competition ELISA.

Results: We found increased CSF levels of 8-iso-PGF2α in patients with MS compared to controls, with the most striking values in a subgroup of patients with SPMS. Furthermore, the increase in 8-iso-PGF2α correlated with other parameters of lipid peroxidation as well as with a decrease in the total antioxidant status in the MS CSF samples.

Conclusions: Our study demonstrates that CSF levels of 8-iso-PGF2α may serve as a biomarker of oxidative stress in MS. Further investigation will help establish the pathologic and clinical significance of our preliminary findings.

No MeSH data available.


Related in: MedlinePlus